


Topiramate

Chemical Properties

CAS No. :	97240-79-4
Formula:	C ₁₂ H ₂₁ N ₀ S ₈
Molecular Weight:	339.36
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Topiramate (RWJ 17021) is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.
Targets(IC50)	Calcium Channel, GABA Receptor, GluR, Carbonic Anhydrase, iGluR, Potassium Channel, Sodium Channel
In vitro	Intraperitoneal injection of 20 and 40 mg/kg topiramate demonstrated a dose-dependent inhibition of both tonic convulsions and absence seizures. Intraperitoneal administration of topiramate at doses ranging from 25-100 mg/kg dose-dependently increased the threshold for pentylenetetrazol (PTZ)-induced clonic seizures. Topiramate was dose-effectively potent in suppressing acute seizures induced by perinatal hypoxia, with an ED ₅₀ of 2.1 mg/kg. Additionally, in DBA/2 mice, topiramate inhibited audiogenic seizures, confirming its anticonvulsant efficacy.
In vivo	In whole-cell voltage-clamp recordings from principal neurons of the basolateral nucleus of the rat amygdala, low concentrations of Topiramate selectively inhibit excitatory postsynaptic currents (EPSCs) mediated by pharmacologically isolated kainate receptors that contain the GluR5 subunit. Topiramate also noticeably reduces AMPA receptor-mediated EPSCs, albeit with less potency. Additionally, Topiramate slightly inhibits the sustained component of Na ⁺ currents in isolated neurons, and after blocking Ca ²⁺ and K ⁺ currents, diminishes the peak of Na ⁺ -dependent persistent action potentials induced in layer V pyramidal neurons. The compound selectively inhibits synaptic responses mediated by the GluR5 kainate receptor. Moreover, Topiramate impedes the action of voltage-sensitive Na ⁺ channels and non-N-methyl-D-aspartate receptors, while potentiating inhibition mediated by gamma-aminobutyric acid (GABA).

Solubility Information

Solubility	DMSO: 260 mg/mL (766.15 mM), Sonication is recommended. Ethanol: 130 mg/mL (383.07 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.89 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may</i>

A DRUG SCREENING EXPERT

In vivo Formulation	<i>vary and should be modified based on specific experimental conditions.</i>
---------------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9467 mL	14.7336 mL	29.4672 mL
5 mM	0.5893 mL	2.9467 mL	5.8934 mL
10 mM	0.2947 mL	1.4734 mL	2.9467 mL
50 mM	0.0589 mL	0.2947 mL	0.5893 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Taverna S, et al. J Pharmacol Exp Ther, 1999, 288(3), 960-968.
- Gryder DS, et al. J Neurosci, 2003, 23(18), 7069-7074.
- Yang Y, et al. Brain Res, 1998, 804(2), 169-176.
- Kaminski RM, et al. Neuropharmacology, 2004, 46(8), 1097-1104.
- Koh S, et al. Ann Neurol, 2001, 50(3), 366-372.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481